A group of investors including former booking.com top executive Kees Koolen has invested 10 million in medtech MyTomorrows. This Dutch startup helps physicians and patients access potentially life-saving drugs that are still in development and not yet approved. Koolen invests via the Swedish investment fund EQT Ventures.
Like many startups, MyTomorrows was born out of frustration. Founder and CEO Ronald Brus (former executive of biotech Crucell) founded the company after his own father couldn’t receive new experimental treatments in time for terminal lung cancer that proved to be successful in early clinical testing. After this personal experience, Brus concluded that the development of new medication that could help (terminally) ill patients took too long. With MyTomorrows, Brus aims to speed up prescriptions of these experimental drugs for patients of who needs them the most.